You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 19, 2025

CLINICAL TRIALS PROFILE FOR ARICEPT


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Aricept

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000173 ↗ Memory Impairment Study (Mild Cognitive Impairment Study) Completed Alzheimer's Disease Cooperative Study (ADCS) Phase 3 1999-03-01 The National Institute on Aging (NIA) is launching a nationwide treatment study targeting individuals with mild cognitive impairment (MCI), a condition characterized by a memory deficit, but not dementia. An NIA-funded study recently confirmed that MCI is different from both dementia and normal age-related changes in memory. Accurate and early evaluation and treatment of MCI individuals might prevent further cognitive decline, including development of Alzheimer's disease (AD). The Memory Impairment Study is the first such AD prevention clinical trial carried out by NIH, and will be conducted at 65-80 medical research institutions located in the United States and Canada. This study will test the usefulness of two drugs to slow or stop the conversion from MCI to AD. The trial will evaluate placebo, vitamin E, and donepezil, an investigational agent approved by the Food and Drug Administration for another use. Vitamin E (alpha-tocopherol) is thought to have antioxidant properties, and was shown in a 1997 study to delay important dementia milestones, such as patients' institutionalization or progression to severe dementia, by about seven months.
NCT00000173 ↗ Memory Impairment Study (Mild Cognitive Impairment Study) Completed National Institute on Aging (NIA) Phase 3 1999-03-01 The National Institute on Aging (NIA) is launching a nationwide treatment study targeting individuals with mild cognitive impairment (MCI), a condition characterized by a memory deficit, but not dementia. An NIA-funded study recently confirmed that MCI is different from both dementia and normal age-related changes in memory. Accurate and early evaluation and treatment of MCI individuals might prevent further cognitive decline, including development of Alzheimer's disease (AD). The Memory Impairment Study is the first such AD prevention clinical trial carried out by NIH, and will be conducted at 65-80 medical research institutions located in the United States and Canada. This study will test the usefulness of two drugs to slow or stop the conversion from MCI to AD. The trial will evaluate placebo, vitamin E, and donepezil, an investigational agent approved by the Food and Drug Administration for another use. Vitamin E (alpha-tocopherol) is thought to have antioxidant properties, and was shown in a 1997 study to delay important dementia milestones, such as patients' institutionalization or progression to severe dementia, by about seven months.
NCT00004807 ↗ Study of the Pathogenesis of Rett Syndrome Completed Johns Hopkins University N/A 1995-01-01 OBJECTIVES: I. Extend current knowledge of the phenotype and natural history of Rett syndrome (RS). II. Continue the search for a cytogenetic and/or DNA marker. III. Study the effects of cholinergic drugs based on preliminary evidence for reduced levels of brain acetylcholine, while continuing supportive care to modify seizures, respiratory abnormalities, and motor disturbances, and improve nutrition, behavior, and learning. IV. Identify targets for future therapeutic interventions, e.g., growth factors, to influence neurologic recovery.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Aricept

Condition Name

Condition Name for Aricept
Intervention Trials
Alzheimer's Disease 36
Alzheimer Disease 22
Healthy 14
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Aricept
Intervention Trials
Alzheimer Disease 67
Dementia 25
Cognitive Dysfunction 19
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Aricept

Trials by Country

Trials by Country for Aricept
Location Trials
United States 340
Canada 46
Japan 28
Korea, Republic of 25
United Kingdom 23
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Aricept
Location Trials
California 25
Texas 21
Florida 21
New York 18
Arizona 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Aricept

Clinical Trial Phase

Clinical Trial Phase for Aricept
Clinical Trial Phase Trials
Phase 4 32
Phase 3 21
Phase 2/Phase 3 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Aricept
Clinical Trial Phase Trials
Completed 111
Terminated 16
Unknown status 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Aricept

Sponsor Name

Sponsor Name for Aricept
Sponsor Trials
Pfizer 18
Eisai Inc. 15
National Institute of Mental Health (NIMH) 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Aricept
Sponsor Trials
Industry 118
Other 91
NIH 25
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Aricept in the Alzheimer's Disease Landscape: Clinical Trials, Market Analysis, and Projections

Introduction to Aricept

Aricept, also known by its generic name donepezil, is a widely used medication for managing the symptoms of Alzheimer's disease. It belongs to the class of cholinesterase inhibitors, which work by increasing the levels of acetylcholine in the brain, thereby improving cognitive function and memory.

Clinical Trials and Efficacy

While Aricept itself is not currently in new clinical trials, its efficacy and safety have been well-established over the years. However, the broader context of Alzheimer's disease research provides insights into how treatments like Aricept fit into the overall therapeutic landscape.

  • Existing Efficacy: Studies have shown that donepezil can improve cognitive function and quality of life for patients with mild to moderate Alzheimer's disease. However, it does not halt the progression of the disease[5].

  • Comparison with New Therapies: Recent clinical trials have focused on more innovative treatments such as monoclonal antibodies (e.g., aducanumab and lecanemab) and BACE inhibitors, which target the disease at earlier stages and aim for more significant therapeutic benefits. These new therapies are expected to change the treatment landscape, potentially reducing the reliance on symptomatic treatments like Aricept[2][3].

Market Analysis

Current Market Position

  • Sales and Market Share: As of the latest forecasts, Aricept remains a significant player in the Alzheimer's disease market, although its sales are expected to be overshadowed by newer therapies. For instance, GlobalData forecasts that Aricept will generate total sales of $762 million between 2023 and 2028, which is significantly lower than the projected sales of newer drugs like lecanemab (Leqembi)[3].

Market Trends and Projections

  • Global Market Growth: The Alzheimer's disease market is expected to grow at a strong Compound Annual Growth Rate (CAGR) of 17.5% from 2016 to 2026, driven by the increasing prevalence of Alzheimer's and mild cognitive impairment (MCI), as well as the introduction of new disease-modifying therapies (DMTs)[2].

  • Regional Market: The U.S. market is a significant contributor to Aricept's sales, with North America holding a substantial share of the global donepezil market. However, the Asia-Pacific region is expected to exhibit the fastest growth rate due to increasing healthcare expenditure and growing awareness of personalized medicine[5].

Impact of New Therapies on Aricept

Emerging Competitors

  • Monoclonal Antibodies: Drugs like lecanemab (Leqembi) and aducanumab are expected to dominate the market with their ability to target amyloid beta plaques and slow cognitive decline. Leqembi, for example, is forecasted to generate $12.9 billion in sales between 2023 and 2028, significantly outpacing Aricept's projected sales[3].

  • BACE Inhibitors: Another class of drugs, BACE inhibitors (e.g., verubecestat and lanabecestat), although not as lucrative as monoclonal antibodies, are expected to be widely prescribed due to their oral administration and affordability. These drugs are designed to interrupt the amyloid beta production pathway, offering a different therapeutic approach[2].

Future of Aricept in the Treatment Landscape

Changing Prescribing Patterns

  • As new drug classes enter the market, prescribing patterns in the Alzheimer's disease population are expected to change significantly. Physicians anticipate that future treatments will involve combination therapies rather than single-agent treatments, which could reduce the reliance on symptomatic treatments like Aricept[2].

Role in Combination Therapies

  • While Aricept may not be the primary treatment in the future, it could still play a role in combination therapies. Its ability to manage symptoms could complement the disease-modifying effects of newer therapies, potentially enhancing overall patient outcomes.

Key Takeaways

  • Established Efficacy: Aricept remains effective in managing symptoms of Alzheimer's disease but does not address the underlying disease progression.
  • Market Position: Aricept's sales are expected to be overshadowed by newer, more innovative therapies.
  • Emerging Competitors: Monoclonal antibodies and BACE inhibitors are changing the treatment landscape and are forecasted to dominate the market.
  • Future Role: Aricept may continue to be used in combination therapies to manage symptoms while newer drugs target the disease's progression.

FAQs

What is Aricept used for?

Aricept, or donepezil, is used to manage the symptoms of Alzheimer's disease, particularly improving cognitive function and memory by increasing acetylcholine levels in the brain.

How does Aricept compare to newer Alzheimer's treatments?

Aricept is a symptomatic treatment, whereas newer therapies like monoclonal antibodies (e.g., lecanemab) and BACE inhibitors are designed to modify the disease process, targeting amyloid beta plaques and production pathways.

What is the projected market performance of Aricept?

Aricept is forecasted to generate $762 million in sales between 2023 and 2028, which is significantly lower than the projected sales of newer drugs like lecanemab (Leqembi)[3].

Will Aricept continue to be prescribed in the future?

Yes, Aricept may continue to be prescribed, particularly in combination with newer disease-modifying therapies to manage symptoms and enhance overall patient outcomes.

How is the Alzheimer's disease market expected to grow?

The Alzheimer's disease market is expected to grow at a CAGR of 17.5% from 2016 to 2026, driven by the increasing prevalence of Alzheimer's and the introduction of new therapies[2].

Sources

  1. Current therapeutics for Alzheimer's disease and clinical trials - Exploration Pub.
  2. MARKET BRIEF - Alzheimer's Disease Market Report (2016-2026) - GlobalData.
  3. Alzheimer's drug Leqembi will generate $12.9 billion in sales by 2028, forecasts GlobalData - GlobalData.
  4. NIA-Funded Active Alzheimer's and Related Dementias Clinical Trials - National Institute on Aging.
  5. Donepezil Market Size, Share, Trends & Growth Statistics, 2033 - Allied Market Research.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.